Dr. Ralf Fink
In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during
development due to these challenging properties. The solubilization of actives is therefore an important approach towards
improving the bioavailability of a drug molecule in an accepted dosage form.
In this special issue, BASF would like to open up a discussion about solubilization challenges and innovative solutions, focusing
on both products and cost-effective production technologies, such as hot-melt extrusion and spray drying. Because innovation
is always the result of many, companies such as Catalent, Bend Research and Johnson & Johnson have also contributed with their
expertise on this topic.
True to its legacy of innovation, BASF continues to develop new innovative solubilizers, such as Soluplus®. Thus, together
with our established portfolio of Kolliphor® solubilizers and Kollisolv® cosolvents, we offer a versatile toolbox capable
of coping with the many solubilization challenges facing our industry. This, in combination with our SoluHTS® screening robot,
enables the industry to screen and identify the most suitable solubilization excipients faster, thereby shortening their product
In the end, there is no single way out of the "maze of pharmaceutical development." However, the use of new technologies and
innovative products may get us out quicker.
Dr. Ralf Fink
Vice-President of Global Marketing,
BASF Pharma Ingredients & Services